United Kingdom side effects

Prior to the tests, all the samples were dried in a vacuum oven at 80°C for at least 72 h to minimize the moisture effect and then transferred to a desiccator. Measurements were carried out on a cone calorimeter provided by the Dark Star Research Ltd., United Kingdom. To minimize the conduction heat losses to insulation and to provide well-defined boundary conditions for numerical analysis of these tests, a sample holder was constructed as reported in [14] with four layers (each layer is 3 mm thick) of Cotronic ceramic paper at the back of the sample and four layers at the sides. A schematic view of the sample holder is shown in Figure 19.12. Three external heat fluxes (40, 50, and 60kW/m2) were used with duplicated tests at each heat flux. 

Toxicity. Indoprofen was suspended from use in the United Kingdom in December 1983 because of reports of side-effects and fatalities. 

This compound chelates cyanide as cobalticyanide. This drug is known to antagonize cyanide more quickly than the nitrites but its clear superiority has not been established. Intravenous administration of 300 mg of dicobalt edetate in glucose solution is the current treatment of choice in France and the United Kingdom. Serious side effects like vomiting, urticaria, anaphylactoid shock, hypotension, and ventricular arrythmias have been reported in patients receiving Kelocyanor (Van Heijst and Meredith, 1990). 

Due to the inhibition of MAO-B, (-)-deprenyl treatment allows for a 20-50% decrease in the levodopa dose needed in Parkinson s disease. In patients who need levodopa, however, there is always a risk that the administration of (-)-deprenyl will enhance the side effects of levodopa, which can only be avoided by properly decreasing the levodopa dose according to the individual sensitivity of the patient. An example of a multicenter clinical trial in which the improper combination of levodopa with (-)-deprenyl led to confusion and misinterpretation is the one performed by the Parkinson s Disease Research Group of the United Kingdom (PDRG-UK) (Lees 1995). 

In addition to the desire for immediate symptom improvement, prevention of mastoiditis and meningitis has been suggested as a reason to prescribe immediate antibiotic treatment for acute otitis media. The rates of mastoiditis in the Netherlands, Norway, and Denmark (all countries in which delayed therapy has been adopted) and those in Canada, the United States, Austraha, and the United Kingdom were compared. The delay of antibiotic use resulted in an increase from about 2 to 4 cases of mastoiditis per 100,000 children per year, accompanied by about 1600 fewer children per 100,000 experiencing antibiotic side effects. Of note, in the Netherlands, only 1.1% of infections caused by S. pneumoniae are penicUhn-resistant. 

A. Pralidoxime chloride (2-PAM) is the only oxime currently approved for use in the United States. Oximes differ in their effectiveness against specific agents, dose, and side-effect profile. In the United Kingdom, the methanesulfonate salt of pralidoxime, P2S, is used. In other European countries and South Africa, TMB4 and obidoxime (Toxogonin) are employed. 2-PAM methiodide is used in Japan. 

---